Ivan Deweber

Cortex Discovery’s in silico drug discovery platform is based on its leading-edge AI technology which can predict molecule properties in all therapeutic fields. The accuracy of its predictions has been validated in the lab, and rivals that of experiments. Cortex is also developing a next-generation molecular docking technology, which combines deep learning with quantum molecular simulations to deliver unparalleled accuracy and speed when exploring new targets. Cortex’s comprehensive services cover the entire spectrum of preclinical drug development, from Hit Discovery to Lead Optimization. These offerings encompass virtual High Throughput Screening, ADMET property predictions, Off-target effect predictions, and Hit Analog virtual screening. Cortex also offers milestone-based collaborations. By combining hit discovery with lead optimization in a single powerful step, Cortex achieves a profound reduction in costs, a remarkable enhancement in efficacy, and expedited processes, ensuring considerably faster results. At Cortex, our mission is to contribute to longer and healthier lives, which is why we are actively initiating collaborations to develop our in-house pipeline of compounds for age-related disorders and life extension. #drugdiscovery #AI #deeplearning #biotech #pharma #hitdiscovery #leadoptimization #virtualscreening #hts #adme #toxicity #pharmacology #longevity #lifeextension #cortexdiscovery